drugset
drugset / Trial / NCT05587478

A Study of EDP-323 in Healthy Subjects

NCT05587478 ↗

Phase 1 Completed 82 enrolled Enanta Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.

Timeline

Start
2022-09-29
Primary completion
2023-03-29
Completion
2023-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-323 Unknown — Oral

Indications

respiratory syncytial virus infectious disease